Nomenclature of the Novel Coronavirus and Related Diseases: A Critical Examination
The emergence of the novel coronavirus in late 2019 and its rapid global spread prompted urgent efforts to classify both the virus and the disease it causes. By February 23, 2020, China had reported over 77,000 confirmed infections and 2,000 fatalities linked to the outbreak of viral pneumonia. Two major entities—the World Health Organization (WHO) and the International Committee on Taxonomy of Viruses (ICTV)—proposed distinct nomenclatures: “coronavirus disease 2019 (COVID-19)” for the illness and “severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)” for the virus itself. However, these designations sparked debates among scientists, virologists, and public health experts in China, who highlighted scientific inconsistencies and potential public misunderstandings arising from the names. This article examines these controversies, the arguments for revised terminology, and the broader implications of nomenclature choices.
Initial Classification Efforts
The WHO formally designated the disease caused by the virus as COVID-19 on February 11, 2020, emphasizing the year of discovery, the pathogen family (coronavirus), and the absence of stigmatizing geographic or cultural references. Shortly afterward, the ICTV assigned the virus the name SARS-CoV-2, citing genomic similarities (approximately 79% identity) to the 2003 SARS-CoV virus. While these decisions aimed to standardize global communication, critics argued that the names failed to account for critical differences in virology, epidemiology, and clinical outcomes between SARS-CoV-2 and its predecessor.
Scientific Challenges to the SARS-CoV-2 Designation
Virological Distinctions
Comparative genomic analyses revealed that SARS-CoV-2 shares only 79% of its genome with SARS-CoV, a divergence significant enough to classify it as a distinct viral species. Furthermore, evolutionary studies suggested differing intermediate hosts: while SARS-CoV likely originated in bats and spread via civet cats, SARS-CoV-2’s intermediate host remains unclear, though pangolins and other animals have been proposed. These distinctions, combined with differences in receptor binding (SARS-CoV-2 primarily binds to ACE2 receptors with higher affinity than SARS-CoV), underscore its uniqueness.
Epidemiological and Clinical Differences
Clinically, SARS-CoV-2 exhibits lower pathogenicity than SARS-CoV. During the 2003 SARS outbreak, over 40% of patients developed severe acute respiratory syndrome (SARS), with a case fatality rate (CFR) of 10%. In contrast, COVID-19 manifests as mild or moderate disease in 80% of cases, with severe or critical pneumonia occurring in 10–15% and an overall CFR of 3%. Notably, asymptomatic and presymptomatic transmission, absent in SARS-CoV, complicates containment efforts for SARS-CoV-2.
Public Health Implications
Experts warned that the “SARS-CoV-2” label risks conflating the two viruses in public perception. Associating the new virus with SARS could lead to complacency, as policymakers and communities might assume existing SARS-specific countermeasures (e.g., diagnostics, vaccines) are directly applicable. This assumption is flawed: SARS-CoV-2’s spike protein structure, replication mechanisms, and immune evasion strategies differ substantially from SARS-CoV, necessitating tailored therapeutic and preventive approaches.
Proposals for Revised Nomenclature
Human Coronavirus 2019 (HCoV-19)
Dr. Gui-Zhen Wu, a leading biosafety expert, proposed “HCoV-19” to align the virus’s name with the disease (COVID-19) and to avoid confusion with SARS-CoV. Historically, human coronaviruses like HCoV-OC43 and HCoV-229E were named using a combination of identifiers (e.g., lab codes, discovery locations). HCoV-19 follows this convention while emphasizing its novel status and distinctness from zoonotic coronaviruses like SARS-CoV or MERS-CoV.
2019 Acute Respiratory Syndrome Coronavirus (TARS-CoV)
Dr. Jian-Qing Xu, a virologist, suggested “TARS-CoV” (2019 Acute Respiratory Syndrome Coronavirus) to reflect clinical outcomes without evoking SARS-related stigma. Unlike highly pathogenic zoonotic coronaviruses, TARS-CoV occupies an intermediate niche, causing severe disease in a minority but exhibiting sustained human-to-human transmission. This name differentiates it from seasonal human coronaviruses (e.g., HCoV-NL63) and emphasizes its unique epidemiological trajectory.
Taxonomy-Based Approaches
Dr. Jian-Wei Wang advocated for integrating the virus into existing coronavirus genera (α, β, γ, δ) or adopting a year-based system akin to influenza naming (e.g., H1N1/2009pdm). A β-coronavirus classification, as with MERS-CoV, would situate SARS-CoV-2 within its phylogenetic lineage while avoiding misleading associations with SARS.
Historical Context and Naming Conventions
Coronavirus nomenclature has evolved inconsistently. Early human coronaviruses (HCoV-229E, HCoV-OC43) were named after lab identifiers, while SARS-CoV and MERS-CoV derived their names from clinical syndromes and geographic regions. This ad hoc approach created ambiguity, as names conflated disease severity, host species, and discovery contexts.
The 2015 WHO guidelines for naming diseases, which discourage references to locations, animals, or cultural groups, were partially followed in COVID-19. However, ICTV’s reliance on genomic homology over clinical or epidemiological factors led to the contentious SARS-CoV-2 label. Critics argued that taxonomy must balance genetic relatedness with practical considerations, such as public communication and clinical management.
Implications of Nomenclature Choices
Public Perception and Stigma
Names shape public understanding and behavior. Associating SARS-CoV-2 with SARS risks unnecessary panic or, conversely, underestimation of its threat. For instance, the 3% CFR of COVID-19 is lower than SARS’s 10%, but its higher transmissibility has caused far greater global morbidity and mortality. Clear, distinct naming helps communities contextualize risks and adhere to prevention measures.
Research and Policy Coordination
Ambiguous terminology impedes research clarity. For example, studies on SARS-CoV immunity or therapies might be erroneously cited as relevant to SARS-CoV-2, wasting resources. Similarly, public health policies (e.g., travel restrictions, quarantine protocols) require precise terminology to avoid legal or logistical conflicts.
Long-Term Surveillance
Experts warned that COVID-19 may transition from pandemic to endemic, recurring seasonally like influenza. A name like SARS-CoV-2 could become anachronistic, whereas HCoV-19 or TARS-CoV provides a neutral, enduring identifier adaptable to future research.
Toward a Standardized Naming Framework
The controversy underscores the need for standardized nomenclature guidelines that integrate virological, clinical, and social factors. Proposed principles include:
- Genetic and Clinical Alignment: Names should reflect both genomic lineage and disease characteristics.
- Temporal References: Incorporating the year of discovery (e.g., HCoV-19) aids in tracking viral evolution.
- Avoiding Stigma: Geographic or ethnic references should be excluded to prevent discrimination.
- Flexibility: Names must adapt to new findings, such as intermediate host identification or increased pathogenicity.
Conclusion
The debate over naming SARS-CoV-2 and COVID-19 highlights the intersection of science, communication, and public policy. While ICTV’s genomic classification has taxonomic validity, it neglects the practical realities of clinical management and public health. Proposals like HCoV-19 and TARS-CoV offer alternatives that balance scientific rigor with clarity, reducing confusion among professionals and the public alike. Moving forward, harmonizing nomenclature across virological and public health domains will be critical to managing COVID-19 and future emerging infectious threats.
doi.org/10.1097/CM9.0000000000000787
Was this helpful?
0 / 0